DK1256339T3 - Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom - Google Patents

Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom

Info

Publication number
DK1256339T3
DK1256339T3 DK01111109T DK01111109T DK1256339T3 DK 1256339 T3 DK1256339 T3 DK 1256339T3 DK 01111109 T DK01111109 T DK 01111109T DK 01111109 T DK01111109 T DK 01111109T DK 1256339 T3 DK1256339 T3 DK 1256339T3
Authority
DK
Denmark
Prior art keywords
rotigotine
parkinson
therapeutic system
transdermal therapeutic
disease
Prior art date
Application number
DK01111109T
Other languages
English (en)
Inventor
Thomas Dr Lauterbach
Dietrich Wilhelm Schacht
Hans-Michael Dr Wolff
Walter Dr Mueller
Original Assignee
Sanol Arznei Schwarz Gmbh
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1256339(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh, Lohmann Therapie Syst Lts filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of DK1256339T3 publication Critical patent/DK1256339T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK01111109T 2001-05-08 2001-05-08 Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom DK1256339T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111109A EP1256339B1 (en) 2001-05-08 2001-05-08 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine

Publications (1)

Publication Number Publication Date
DK1256339T3 true DK1256339T3 (da) 2004-02-09

Family

ID=8177356

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01111109T DK1256339T3 (da) 2001-05-08 2001-05-08 Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
DK02740569T DK1471892T3 (da) 2001-05-08 2002-05-06 Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02740569T DK1471892T3 (da) 2001-05-08 2002-05-06 Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer

Country Status (15)

Country Link
EP (3) EP1344522A1 (da)
JP (2) JP5026656B2 (da)
KR (1) KR100974974B1 (da)
CN (2) CN102172351B (da)
AT (2) ATE251901T1 (da)
CY (1) CY1109861T1 (da)
DE (2) DE60100994T2 (da)
DK (2) DK1256339T3 (da)
ES (2) ES2204780T3 (da)
HK (1) HK1049444B (da)
HU (1) HU229350B1 (da)
PT (2) PT1256339E (da)
RU (1) RU2272625C2 (da)
WO (1) WO2002089778A2 (da)
ZA (1) ZA200209982B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60100595T2 (de) * 2001-05-08 2004-06-24 Lts Lohmann Therapie-Systeme Ag Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2006039532A2 (en) * 2004-09-29 2006-04-13 Schwarz Pharma, Inc. Transdermal therapeutic system for parkinson’s disease
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
WO2011048491A2 (en) * 2009-10-19 2011-04-28 Actavis Group Ptc Ehf Amorphous rotigotine co-precipitates
DK2515887T3 (da) 2009-12-22 2018-09-17 Ucb Biopharma Sprl Polyvinylpyrrolidon til stabilisering af en faststofdispersion af den ikke-krystallinske form af rotigotin
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
DE102014114282A1 (de) 2014-10-01 2016-04-07 Neuraxpharm Arzneimittel Gmbh Transdermales therapeutisches System mit Rotigotin zur Behandlung von Morbus Parkinson
WO2018123822A1 (ja) 2016-12-28 2018-07-05 久光製薬株式会社 ブトルファノール含有貼付剤
DE102018120506A1 (de) 2017-10-20 2019-04-25 Amw Gmbh Stabilisiertes transdermales Darreichungssystem
EP3854388B1 (de) 2020-01-24 2023-10-04 Luye Pharma Switzerland AG Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751515B2 (ja) * 1986-09-10 1995-06-05 明治製菓株式会社 経皮吸収製剤
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten

Also Published As

Publication number Publication date
KR20030016373A (ko) 2003-02-26
JP5026656B2 (ja) 2012-09-12
KR100974974B1 (ko) 2010-08-09
CN102172351A (zh) 2011-09-07
WO2002089778A3 (en) 2004-08-19
EP1256339B1 (en) 2003-10-15
HUP0500525A2 (hu) 2005-09-28
EP1471892A2 (en) 2004-11-03
DE60233898D1 (de) 2009-11-12
ATE444061T1 (de) 2009-10-15
EP1344522A1 (en) 2003-09-17
CN1606435A (zh) 2005-04-13
DE60100994D1 (de) 2003-11-20
PT1256339E (pt) 2004-02-27
JP2004536054A (ja) 2004-12-02
DK1471892T3 (da) 2009-12-07
EP1471892B1 (en) 2009-09-30
ES2204780T3 (es) 2004-05-01
PT1471892E (pt) 2009-12-23
HK1049444A1 (en) 2003-05-16
ZA200209982B (en) 2003-03-24
HK1049444B (zh) 2004-03-19
RU2272625C2 (ru) 2006-03-27
WO2002089778A2 (en) 2002-11-14
ES2331787T3 (es) 2010-01-15
RU2003133217A (ru) 2005-04-20
HU229350B1 (en) 2013-11-28
ATE251901T1 (de) 2003-11-15
DE60100994T2 (de) 2004-07-22
CY1109861T1 (el) 2014-09-10
JP2010106037A (ja) 2010-05-13
CN102172351B (zh) 2013-07-17
EP1256339A1 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
DK1392256T3 (da) Forbedret transdermalt behandlingssystem til behandling af Parkinsons sygdom
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
DE60211139D1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
GEP201606538B (en) Preoperative treatment of post operative pain
SE0102887D0 (sv) New formulation
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
TR200301916T4 (tr) Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem.